tert-butyl 5-cyanoindoline-1-carboxylate | 874841-30-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: tert-butyl 5-cyanoindoline-1-carboxylate
• 英文别名: tert-butyl 5-cyano-2,3-dihydroindole-1-carboxylate
• CAS: 874841-30-2
• 化学式: C₁₄H₁₆N₂O₂
• 分子量: 244.293
• InChiKey: KDJNHMDZHOBDOJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  53.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl 5-cyanoindoline-1-carboxylate 在 羟胺 作用下， 以 乙醇 、 水 为溶剂， 生成 tert-butyl 5-(N'-hydroxycarbamimidoyl)indoline-1-carboxylate
  参考文献：
  名称：

  Discovery and characterization of potent and selective 4-oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl)butanoic acids as S1P1 agonists

  摘要：

  S1P(1) receptor driven lymphopenia has proven utility in the treatment of an array of autoimmune disease states. As a part of our efforts to develop potent and selective S1P(1) receptor agonists, we have identified a novel chemical series of 4-oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl) butanoic acid S1P(1) receptor agonists. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.05.110
• 作为产物：
  描述：

  二碳酸二叔丁酯 、 5-吲哚啉甲腈 以 四氢呋喃 为溶剂， 生成 tert-butyl 5-cyanoindoline-1-carboxylate
  参考文献：
  名称：

  Discovery and characterization of potent and selective 4-oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl)butanoic acids as S1P1 agonists

  摘要：

  S1P(1) receptor driven lymphopenia has proven utility in the treatment of an array of autoimmune disease states. As a part of our efforts to develop potent and selective S1P(1) receptor agonists, we have identified a novel chemical series of 4-oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl) butanoic acid S1P(1) receptor agonists. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.05.110

文献信息

• Improved Substrate Scope in the Potassium Hexacyanoferrate(II)-Based Cyanation for the Synthesis of Benzonitriles and Their Heterocyclic Analogues
  作者：Jeffery Richardson、Simon P. Mutton

  DOI：10.1021/acs.joc.8b00515

  日期：2018.5.4

  The use of Pd(DPEPhos)Cl2 (P26) as a catalyst for the formation of benzonitriles and their heterocyclic analogues provides excellent complementarity to existing catalysts, allowing highly electron-deficient heterocyclic aryl halides to be efficiently converted to the corresponding nitriles using K4[Fe(CN)6]) as cyanide source. This catalyst significantly enhances the scope of this reaction to include

  使用Pd（DPEPhos）Cl 2（P26）作为形成苄腈及其杂环类似物的催化剂可提供与现有催化剂的出色互补性，从而使高度缺电子的杂环芳基卤化物可通过K 4有效地转化为相应的腈[Fe（CN）6]）作为氰化物源。该催化剂大大增加了反应的范围，使其包含许多与制药和农业化学应用高度相关的底物。重要的是，这种氰化方法不仅使用无毒的氰化物源，简单的半定量测试表明，与许多其他方法不同，反应混合物中或在各种潜在的后处理过程中均不存在游离氰化物，从而提高了该方法的安全性。从初始设置到产品隔离。最终，开发和测试了一系列方便的氰化试剂盒，使得该方法易于应用，并在我们的实验室中得到了更广泛的采用。
• Indolyl-thienopyrazinone derivatives useful for treating hyperproliferative disorders and diseases associated with angiogenesis
  申请人：Cook James

  公开号：US20070105851A1

  公开（公告）日：2007-05-10

  This invention relates to a compound of Formula (I): (I) and its use in treating hyper-proliferative disorders and diseases associated with angiogenesis.

  本发明涉及一种式（I）的化合物：（I），以及其在治疗与血管生成相关的高增殖性疾病和疾病中的应用。
• Novel Indole Derivatives, Preparation Thereof as Medicinal Products and Pharmaceutical Compositions, and Especially as KDR Inhibitors
  申请人：UGOLINI Antonio

  公开号：US20090253697A1

  公开（公告）日：2009-10-08

  The disclosure relates to compounds of formula (I): wherein R1, R2, and R3 are as defined in the disclosure, compositions comprising said compounds, methods for their preparation, intermediates thereto, and the use thereof, particularly as medicaments.

  本公开涉及公式（I）的化合物：其中R1，R2和R3如本公开所定义，包含所述化合物的组合物，其制备方法，其中间体以及其用途，特别是作为药物。
• Discovery and characterization of potent and selective 4-oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl)butanoic acids as S1P1 agonists
  作者：Daniel Buzard、Sangdon Han、Lars Thoresen、Jeanne Moody、Luis Lopez、Andrew Kawasaki、Thomas Schrader、Carleton Sage、Yinghong Gao、Jeff Edwards、Jeremy Barden、Jayant Thatte、Lixia Fu、Michelle Solomon、Ling Liu、Hussien Al-Shamma、Joel Gatlin、Minh Le、Charles Xing、Sheryll Espinola、Robert M. Jones

  DOI：10.1016/j.bmcl.2011.05.110

  日期：2011.10

  S1P(1) receptor driven lymphopenia has proven utility in the treatment of an array of autoimmune disease states. As a part of our efforts to develop potent and selective S1P(1) receptor agonists, we have identified a novel chemical series of 4-oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl) butanoic acid S1P(1) receptor agonists. (C) 2011 Elsevier Ltd. All rights reserved.